Nucleoside analogs (NAs) conjugated with galactosyl terminating peptides selectively enter hepatocytes via the asialoglycoprotein receptor and, after intracellular release from the carrier, partly exit from these cells into the bloodstream, resulting in higher concentrations in liver blood than in systemic circulation. Therefore, conjugates of anticancer NAs can be exploited to accomplish a loco-regional noninvasive treatment of liver micrometastases. In the present experiments we studied whether the enhancement of drug levels in liver blood achieved when NAs are given in the coupled form depends on the rate of drug elimination from the bloodstream. Three NAs, adenine arabinoside (ara-A), 5-fluoro-2Ј-deoxyuridine (FUdR), and 2Ј,2Ј-difluorodeoxycytidine, were coupled with lactosaminated human albumin, a galactosyl terminating carrier. In rats that received an intravenous bolus injection of these conjugates, we compared the drug concentrations in liver blood to those in the systemic circulation. We found that enhanced levels of NAs in liver blood were only achieved by administering the conjugates of the drugs (ara-A and FUdR), which are rapidly cleared from the bloodstream. Increased drug levels also were obtained when ara-A and FUdR conjugates were slowly infused (a way of administration often used for anticancer drugs). The experiments also showed that galactosyl terminating conjugates of NAs might have the potential to produce a therapeutic effect only when the coupled drugs are active at low blood concentrations, since the amounts of drugs introduced into hepatocytes and released by these cells in the bloodstream cannot be increased when the receptor for the hepatic uptake of galactosyl terminating peptides is saturated.
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To obtain a selective delivery of nucleoside analogs (NAs) to hepatocytes and reduce their side effects in the treatment of chronic viral hepatitis, these drugs were conjugated with galactosyl terminating peptides, which specifically enter hepatocytes through the asialoglycoprotein receptor (Fiume et al., 1979; 1997) . The validity of this approach was supported by clinical studies in hepatitis B virus-infected patients, which demonstrated an increase in the chemotherapeutic index of adenine arabinoside (ara-A) after conjugation with lactosaminated human albumin (L-HSA) (Torrani Cerenzia et al., 1996; Zarski et al., 2001) .
It was found that NAs, after the intracellular splitting of the bond with the carrier, partly exit from hepatic cells into bloodstream (Fiume et al., 1998; Di Stefano et al., 1999) . Although this release reduces the efficacy of hepatocyte targeting, it has a useful consequence, since it can result in higher NA concentrations in hepatic blood than in systemic circulation (Di Stefano et al., 2000) . Therefore, conjugation of anticancer NAs with galactosyl terminating carriers might be a way to expose neoplastic cells fed by liver sinusoids to enhanced drug levels and accomplish a loco-regional noninvasive treatment of hepatic micrometastases (Di Stefano et al., 2000 , 2002 .
In the regional chemotherapy performed by local infusion, the advantage of drug delivery to the target region depends on the rate of drug elimination from the rest of the body (Ensminger and Gyves, 1983) . In the present experiments we studied whether the local drug exposure advantage achieved in liver when NAs are given as galactosyl terminating conjugates is similarly affected by the rate of elimination from bloodstream of the drugs released by liver cells. Moreover, we investigated the effect on this enhancement of the means of administration of the conjugates (by bolus injection or slow infusion).
We conjugated FUdR, ara-A, and dFdC with L-HSA. ara-A and FUdR are rapidly cleared from blood (Ensminger et al., 1978; Preiksaitis et al., 1981; Di Stefano et al., 2000) , whereas dFdC slowly disappears from bloodstream, at least in rats (Shipley et al., 1992) . In rats injected with ara-A, FUdR, and dFdC, administered in the free or conjugated form, either by bolus injection or by slow infusion, we determined the concentrations of these NAs in hepatic veins and in inferior vena cava. These concentrations are a measure of the drug levels in liver blood and in systemic circulation, respectively.
Materials and Methods
Conjugate Preparation. Lactosaminated albumin (L-HSA) was prepared as described by Wilson (1978) . The lactose/HSA molar ratio was 24. Conjugation of ara-A, [ 3 H]FUdR, and [ 3 H]dFdC was obtained via the imidazolides of their 5Ј-phosphoric esters (Fiume et al., 1993) . Using this procedure, NAs are linked to lysine residues of L-HSA by a phosphate bridge. The drug/L-HSA molar ratio, determined spectrophotometrically, ranged from 13 to 16. Jentoft and Dearborn (1983) . The specific activity was 1.7 ϫ 10 3 dpm/g, which corresponded to 1 [ 14 C]formaldehyde per HSA molecule.
Animals. Male Wistar rats weighing 200 to 220 g were used. They were obtained from Harlan Italy (Udine, Italy) and were maintained in an animal facility at the Department of Experimental Pathology, University of Bologna, receiving humane care in accordance with European Legislation. The protocols of the experiments were approved by the ethical committee of the University of Bologna. Animals were fed a standard pellet diet ad libitum.
Determination of Drugs in Inferior Vena Cava and in Hepatic Veins. Free and conjugated drugs were administered intravenously either by bolus injection or by slow infusion. Bolus injection was performed via the dorsal vein of the penis under ether anesthesia. Infusion was performed via the femoral vein in animals anesthetized by intraperitoneal administration of ketamine/xylazine. The compounds were given in a volume of 0.87 ml, administered in 1 h using an Orion Sage M361 (Expotech, Houston, TX) infusion pump.
Blood sampling from inferior vena cava and from hepatic veins was performed at different times after the bolus injection or at the end of the 1-h infusion period. The procedure described by Di Stefano et al. (2000) was followed. ara-A was measured according to the method of McCann et al. (1985) ]dFdC was calculated, taking into account the recovery of the marker (measured by UV absorbance) and the specific activity of the injected drug. The recovery of the markers was 85 to 95%. The specific activity of free or conjugated drugs was 5.5 ϫ 10 4 dpm/g. When radioactivity of the drug peak was lower than 200 dpm, the plasma concentration of the drug was considered to be below a measurable level. With a 90% recovery of the markers, the lowest measurable plasma concentration was about 20 ng/ml.
In rats receiving a bolus injection of [ 3 H]FU (Amersham Biosciences AB, Uppsala, Sweden) (see below), the drug was extracted from plasma as described for [ 3 H]dFdC and measured by the procedure of isotopic dilution; HPLC analysis was performed using two Spherisorb ODS2 columns connected in series and isocratically eluted with 20 mM sodium tetraborate, pH 7.5. The limit of detection was 20 ng/ml. Figure 1 shows that after administration of ara-[ 3 H]A or [ 3 H]dFdC the levels of radioactivity were similar in liver, spleen and intestine. The finding of higher amounts of radioactivity in kidney of [ 3 H]dFdC-treated rats is in agreement with previous data (Shipley et al., 1992 (Heriot and Kumar, 1998) ], the levels of radioactivity in liver were significantly higher than those in spleen, intestine, and kidney. The radioactivity in kidney was higher than in spleen and intestine.
Results
The rapid disappearance of ara-A (Preiksaitis et al., 1981; Di Stefano et al., 2000) , [ 3 H]FU, and [ 3 H]FUdR (Ensminger et al., 1978) from bloodstream is confirmed by the data of Tables 1 and 2 . Given to rats by bolus injection at the dose of 0.5 g/g, these drugs were not detected in blood of inferior vena cava after 15 to 30 min (the limits of detection were 2 ng/ml for ara-A and 20 ng/ml for both [ 3 H]FU and [ 3 H]FUdR). On the contrary, after administration of [ 3 H]dFdC (0.5 g/g), the drug was still detectable at 8 h (limit of detection ϭ 20 ng/ml) ( Table 3) . Experiments were performed as described by Fiume et al. (1987) H]FU, the values in liver were higher than those in spleen, intestine ‫,ءءء(‬ p Ͻ 0.001) and kidney (EE, p Ͻ 0.01). In the same animals the levels of radioactivity in kidney were higher than those in spleen and intestine (ϩϩϩ, p Ͻ 0.001). , the blood levels of drugs were several times lower in hepatic veins than in inferior vena cava (Table 2) , a result in agreement with data in humans and explained by the ability of hepatic cells to extract fluoropyrimidines from bloodstream (Ensminger et al., 1978; Wagner et al., 1986) . In rats administered [ 3 H]dFdC (bolus injection or infusion) or ara-A (infusion) (two NAs which are not selectively extracted by liver cells) (Fig. 1) , the drug levels were similar in hepatic veins and in inferior vena cava (Tables 1 and 3) . Tables 1 and 2 show that administration of ara-A and [ 3 H]FUdR conjugates produces an increase in drug concentrations in liver blood. In fact, in rats injected with L-HSAcoupled [ 3 H]FUdR or ara-A (0.5 g/g, corresponding to 13 g/g conjugates), the ratios between the drug levels in hepatic veins and those in inferior vena cava were several times higher than in animals administered with the unconjugated drugs.
Enhanced Drug Levels in Liver Blood
The enhancement of drug levels in liver blood was achieved not only in animals which received a bolus injection of the conjugate, but also in rats slowly infused.
In rats injected with L-HSA coupled [ 3 H]dFdC the increase in drug concentrations in liver blood was much lower; it was observed only at the earliest times after the bolus injection and in the animals infused it was statistically significant only for the dose of 0.25 g/g (Table 3) .
After 1 h infusion of the conjugates, the blood levels of drugs were similar in animals administered 13 g/g/h or 26 g/g/h conjugate (Tables 1-3 ). This finding can be explained by assuming that the asialoglycoprotein receptor was saturated with the lower dose, so that by doubling the dosage the amounts of conjugate taken up by the hepatic cells could not be increased. This explanation is supported by the finding that in rats injected with asialofetuin, the maximal clearing capacity of the liver is equivalent to approximately 12 g of protein/g/h (Regoeczi et al., 1978) . Further support comes from the results reported in Fig. 2 : after 1 h of infusion, the values of radioactivity in liver of rats administered 13 g/g/h L-[ 14 C]HSA-FUdR (a conjugate labeled in the carrier moiety) were similar to those of the animals infused with the double dose; on the contrary, the levels of radioactivity in plasma were significantly higher in the latter animals. Data were obtained from three rats and are given as mean Ϯ S.E. When the difference between the drug level in IVC and HV is statistically significant (Student's t test), it is indicated by asterisks (***p Ͻ 0.001).
Drug
Means of a Below measurable level (Ͻ2 ng/ml). b ara-A cannot be administered by bolus injection at doses higher than 2 g/g due to its scarce solubility in water [about 570 g/ml at 25°C (Cohen, 1966) ].
Discussion
Our previous studies showed that administration by peripheral venous route of NAs coupled to galactosyl terminating carriers can result in higher drug levels in liver blood than in systemic circulation (Di Stefano et al., 2000) . This observation suggested that conjugation with these carriers might be a way to expose the neoplastic cells of liver micrometastases, which are nourished by hepatic sinusoids (Haugeberg et al., 1988) , to enhanced concentrations of anticancer NAs. By releasing the drug in liver blood, the conjugates would accomplish a regional chemotherapy similar to that performed by the portal vein infusion of FU (Midgley and Kerr, 1999) . It would have the advantage of administration by the peripheral venous route, which allows much longer treatment than the single 7-day cycle permitted by portal vein infusion.
In the present study we have conjugated L-HSA with ara-A, FUdR, and dFdC and have shown that the enhancement of drug levels in liver blood can only be achieved by using NAs (ara-A, FUdR), which are rapidly cleared from the bloodstream; this result is in agreement with those of regional chemotherapy performed by a local infusion of drugs (Ensminger and Gyves, 1983) . We have also observed that conjugates of rapidly cleared NAs leads to higher drug concentrations locally in liver blood, not only when they are given by bolus injection, but also when they are administered by slow infusion. This finding is relevant since anticancer NAs usually act on DNA synthesis, and administration by slow infusion can be useful to ensure that an increasing proportion of tumor cells are exposed to the antineoplastic effect at a metabolically vulnerable time.
In comparison with the local infusion of drugs, the use of L-HSA conjugates for a regional chemotherapy in liver would have a limitation, since it could be advantageous only when the coupled drugs are active at low concentrations. In fact, the quantities of drugs transported by L-HSA inside the hepatocytes and released from these cells in liver sinusoids could not be enhanced by increasing the dose of the conjugate when the asialoglycoprotein receptor is saturated. According to the present results, FUdR appears to be a suitable drug for the liver regional chemotherapy approach achieved by NA coupling to L-HSA. FUdR is rapidly cleared from the bloodstream, and in the treatment of human colorectal cancer, it is active at very low plasma concentrations (0.2 ng/ml) (Park et . Experiments were performed as described by Fiume et al. (1987) . Acid-insoluble radioactivity was expressed as disintegrations per minute/specific activity/gram or milliliter (dpm/SA/ml or g). Values are means from three animals; bars indicate standard errors. The data were evaluated by Student's t test. ‫,ءءء‬ significant difference (p Ͻ 0.001) only from rats infused with 6.5 g/g/h conjugate. EEE, significant difference (p Ͻ 0.001) from rats infused with 6.5 or 13 g/g/h conjugate. , 1988) , which are several times smaller than those measured in the systemic circulation of rats infused with L-HSAFUdR.
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